NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons

NCT ID: NCT04799392

Last Updated: 2021-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-01

Study Completion Date

2021-10-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

The NOWDx COVID-19 Test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Testing of human fingerstick whole blood is intended to be conducted in a home-like setting of a facility authorized to perform CLIA waived tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 SARS-CoV-2 Coronavirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Persons tested with investigational device following PCR test

Persons tested with investigational device who previously tested positive or negative for COVID-19 with an emergency use authorized or FDA cleared COVID-19 test

Group Type EXPERIMENTAL

NOWDx COVID-19 Test

Intervention Type DEVICE

The investigational device is the NOWDx COVID-19 Test.

Persons tested with investigational device following vaccination

Persons tested with investigational device who previously were vaccinated for COVID-19 with an emergency use authorized or FDA cleared COVID-19 vaccine

Group Type EXPERIMENTAL

NOWDx COVID-19 Test

Intervention Type DEVICE

The investigational device is the NOWDx COVID-19 Test.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NOWDx COVID-19 Test

The investigational device is the NOWDx COVID-19 Test.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Innate Infection Cohort\>

* PCR positives: persons who were symptomatic for COVID-19 and have tested positive for COVID-19 with an EUA or FDA cleared PCR test; 7+ days post positive PCR test
* PCR negatives: persons who have never had COVID-19 and who have tested negative for COVID-19 with an EUA or FDA cleared PCR test; within 0-6 days post negative PCR test
* persons 2+ years old

Vaccination Cohort\>

* persons 7- 60 days post second dose of EUA COVID-19 vaccine
* persons 18+ years old

Exclusion Criteria

Innate Infection Cohort\>

* PCR positives: persons with a COVID-19 positive test result \>45 days old
* PCR negatives: persons with any prior COVID-19 positive result
* persons who have received COVID-19 vaccine
* persons \<2 years old

Vaccination Cohort\>

* persons symptomatic or previously infected with COVID-19 prior to vaccination
* persons \<18 years old
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NOWDiagnostics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Beth Cobb

Role: PRINCIPAL_INVESTIGATOR

NOW Diagnostics, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Arts Pharmacy

Fayetteville, Arkansas, United States

Site Status

Goodrich Pharmacy

Anoka, Minnesota, United States

Site Status

Alps Specialty Pharmacy

Nixa, Missouri, United States

Site Status

Alps Pharmacy

Springfield, Missouri, United States

Site Status

Bremo Pharmacy

Richmond, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NOWDx COVID-19 Antibody OTC

Identifier Type: -

Identifier Source: org_study_id